New Phase 3 trial: Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults — Brise Pharmaceuticals Co., Ltd.
Why now
Thesis: Long-term migraine tablet safety trial registration by Brise
Catalyst to watch: Trial results or regulatory filing updates
Main risk: Sponsor not in allowed ticker set
Why it matters
Long-term safety trial registration for a migraine tablet; sponsor not in allowed ticker set.
Details
Sponsor: Brise Pharmaceuticals Co., Ltd.; Status: Not Yet Recruiting; Conditions: Migraine, With or Without Aura; Interventions: BR005-036C; Enrollment: 1000 (estimated); First posted: 2026-09-22; NCT: NCT07835152
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC